Skip to main content
. Author manuscript; available in PMC: 2021 May 15.
Published in final edited form as: Clin Cancer Res. 2020 Sep 11;26(22):6028–6038. doi: 10.1158/1078-0432.CCR-20-0400

Figure 5. Activity of ICAM1-ADC on primary myeloma cells ex vivo.

Figure 5.

(A) In a representative example shown, ICAM1-ADC selectively decreased the number of viable patient myeloma cells measured by flow cytometry after 48 h treatment, with minimal effect on the normal MNC population (non-PC, black bars). (B) When exposed to graded concentrations for 48 h, ICAM1-ADC but not the control ADC showed potent anti-myeloma activity even at the lowest concentration tested (0.1 nM). (C) In patients screened with 10 nM ICAM1-ADC treatment for 48 h, 3/5 showed a significant reduction of viable myeloma cells, with no observed toxicity in non-PC. (D) Additional samples from patients who were clinically daratumumab-refractory were tested with 10 nM ICAM1-ADC treatment for 48 h, with 2/4 showing a significant reduction of viable myeloma cells. Our anti-ICAM1 monoclonal antibody had a smaller effect. Comparisons in (D) and (D) were made by ANOVA with Tukey’s correction for multiple comparisons. * P < 0.05; ** P < 0.01, *** P < 0.001, **** P < 0.0001. Ctrl ADC – nonbinding isotype control ADC.